Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: April 16, 2026 Report Code: GDHC337PIDR-7M-ST

Report Overview
Key Players
Table of Contents
Table
Figures

According to GlobalData estimates, 2024 base year sales within the VTE market are approximately $3.93 billion across 7MM and will grow at a compound annual growth rate (CAGR) of 2.6% to reach $5.10 billion by the end of the forecast period.

VTE is a disease that includes a myriad of life-threatening disorders ranging from PE to DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity

Scope

Overview of VTE, including epidemiology, symptoms, diagnosis, and disease management.

Annualized VTE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the VTE therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for VTE treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Report deliverables include:

Word report and an Excel-based forecast model

Forecast includes the 7 major markets (7MM)

Forecast covers the period 2022-2032.

The minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period as well as only one late-stage pipeline therapy that will only capture a small share of the market due to its high cost, subcutaneous method of administration, and lack of strong clinical trial data.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM VTE therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Abbvie
Allergan
Alcon
Pfizer
Merck
Santen
Ocular Therapeutix
pH Pharma
Nicox
DWTI
Thea Pharma
Betaliq
Tarsier Pharma

1 Executive Summary

1.1 Market overview

1.2 The VTE market will experience minimal growth between 2024 and 2034

1.3 Companies are focusing clinical trial development on factor XI inhibitors

1.4 Optimal treatment strategies for patients with cancer or renal impairment are needed

1.5 REGN-7508 to contribute moderately to sales during the forecast period

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Diagnosed incident cases of pulmonary embolism, deep vein thrombosis, and VTE

4.4.4 Diagnosed incident cases of deep vein thrombosis by anatomical region

4.4.5 Diagnosed incident cases of VTE by provoking risk factor

4.4.6 Diagnosed incident cases of VTE with cancer as a comorbidity

4.4.7 Diagnosed incident cases of VTE with chronic kidney disease as a comorbidity

4.4.8 Diagnosed VTE attacks

4.4.9 Number of one- and 10-year first-time recurrent cases of VTE

4.4.10 Number of hospital discharges meeting medically ill criteria

4.4.11 Number of hospital discharges meeting medically ill criteria at risk for VTE

4.4.12 Number of total hip and knee replacements

4.5 Epidemiological forecast for VTE, 2024–34

4.5.1 Diagnosed incident cases of pulmonary embolism

4.5.2 Diagnosed incident cases of deep vein thrombosis

4.5.3 Diagnosed incident cases of VTE

4.5.4 Age-specific diagnosed incident cases of VTE

4.5.5 Sex-specific diagnosed incident cases of VTE

4.5.6 Diagnosed incident cases of deep vein thrombosis by anatomical region

4.5.7 Number of diagnosed incident cases of VTE by provoking risk factor

4.5.8 One- and 10-year first-time diagnosed recurrent cases of VTE

4.5.9 Diagnosed incident cases of VTE with cancer as a comorbidity

4.5.10 Diagnosed incident cases of VTE with chronic kidney disease as a comorbidity

4.5.11 Number of diagnosed VTE attacks

4.5.12 Number of hospital discharges meeting medically ill criteria at risk for VTE

4.5.13 Total number of hip replacements

4.5.14 Total number of knee replacements

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.1.1 Treatment

5.1.2 Primary prophylaxis

5.2 Key opinion leader insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Mitigating bleeding risk

7.3 Optimal treatment for cancer patients

7.4 Optimal treatment for patients with renal impairment and renal failure

7.5 Complications associated with parenteral therapies

7.6 Improved education among physicians and patients

8 R&D Strategies

8.1 Overview

8.1.1 Development of drugs with novel targets: factor XI inhibitors

8.2 Clinical trial design

8.2.1 Improvements in quantifying and reporting bleeding risk

8.2.2 Need for trial design that accounts for both short- and long-term clinical outcomes

8.2.3 Comparators for clinical trials based in Japan

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – key opinion leaders interviewed for this report

13.4.1 Key opinion leaders

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Senior Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

List of Tables

Table 1: VTE – key metrics in the 7MM

Table 2: Risk factors and comorbidities for VTE

Table 3: Treatment guidelines for VTE

Table 4: Top 10 deals by value, 2020–25

Table 5: VTE market – global drivers and barriers, 2024–34

Table 6: Key events impacting sales for VTE in the US, 2024–34

Table 7: VTE market – drivers and barriers in the US, 2024–34

Table 8: Key events impacting sales for VTE in the 5EU, 2024–34

Table 9: VTE market – drivers and barriers in the 5EU, 2024–34

Table 10: Key events impacting sales for VTE in Japan, 2024–34

Table 11: VTE market – drivers and barriers in Japan, 2024–34

Table 12: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

List of Figures

Figure 1: Global sales forecast by country for VTE in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in VTE during the forecast period

Figure 3:Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of VTE during the forecast period

Figure 5: Etiology of VTE – Virchow’s triad

Figure 6: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2024

Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PE, DVT, and VTE

Figure 8: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region

Figure 9: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor

Figure 10: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity

Figure 11: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidity

Figure 12: 7MM, sources used to forecast the diagnosed VTE attacks

Figure 13: 7MM, sources used to forecast VTE recurrence after one and 10 years

Figure 14: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE

Figure 15: 7MM, sources used to forecast the primary TKRs and revisions, as well as THRs

Figure 16: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2024

Figure 17: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2024

Figure 18: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2024

Figure 19: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2024

Figure 20: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2024

Figure 21: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2024

Figure 22: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2024

Figure 23: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2024

Figure 24: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2024 and 2034

Figure 25: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2024 and 2034

Figure 26: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2024 and 2034

Figure 27: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, ≥40 years, 2024

Figure 28: 7MM, THRs, N, both sexes, ≥15 years, 2024 and 2034

Figure 29: 7MM, TKRs, N, both sexes, ≥15 years, 2024 and 2034

Figure 30: Treatment algorithm for VTE

Figure 31: Unmet needs and opportunities in VTE

Figure 32: Overview of the development pipeline in VTE

Figure 33: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for VTE in the 7MM during the forecast period

Figure 34: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of VTE during the forecast period

Figure 35: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC: NOACs

Figure 36: Analysis of the company portfolio gap in VTE during the forecast period

Figure 37: 7MM sales forecast by country for VTE in 2024 and 2034

Figure 38: Sales forecast by class for VTE treatment in the US in 2024 and 2034

Figure 39: Sales forecast by class for VTE primary prophylaxis in the US in 2024 and 2034

Figure 40: Sales forecast by country for VTE treatment and primary prophylaxis in the 5EU in 2024 and 2034

Figure 41: Sales forecast by class for VTE treatment and primary prophylaxis in the 5EU in 2024 and 2034

Figure 42: Sales forecast by class for VTE treatment in Japan in 2024 and 2034

Figure 43: Sales forecast by class for VTE primary prophylaxis in Japan in 2024 and 2034

Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Venous Thromboembolism reports

Pharmaceuticals

New

Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence

Pharmaceuticals

New

Q1 2026 CRO Activity and Intel Report

Pharmaceuticals

New

Bio/Pharmaceutical Outsourcing Report, April 2026

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

Access a live Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Scope

Key Highlights

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports